Nieuws

How digital intake solutions driven by technological advancements can help overcome the challenges of operating across ...
Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...
In this video interview, Michel van Harten, MD, CEO, myTomorrows, discusses how patient education and remote monitoring can help with reducing the burden of trial participation.
One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...
In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights how artificial intelligence can be used to address logistical barriers such as access and treatment cost.